More on the Survival and Ventricular Enlargement Trial

C. J. Ganley; H. M J Hung; R. Temple; M. A. Pfeffer; L. A. Moye; J. Rutherford; E. Braunwald

doi:10.1056/NEJM199310143291616

More on the Survival and Ventricular Enlargement Trial

C. J. Ganley, H. M J Hung, R. Temple, M. A. Pfeffer, L. A. Moye, J. Rutherford, E. Braunwald

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)¹ reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves…

Original language	English (US)
Pages (from-to)	1204-1206
Number of pages	3
Journal	New England Journal of Medicine
Volume	329
Issue number	16
DOIs	https://doi.org/10.1056/NEJM199310143291616
State	Published - Oct 14 1993

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199310143291616

Cite this

@article{11e34662c2ce495aac58f8accdf79bfb,

title = "More on the Survival and Ventricular Enlargement Trial",

abstract = "To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves…",

author = "Ganley, {C. J.} and Hung, {H. M J} and R. Temple and Pfeffer, {M. A.} and Moye, {L. A.} and J. Rutherford and E. Braunwald",

year = "1993",

month = oct,

day = "14",

doi = "10.1056/NEJM199310143291616",

language = "English (US)",

volume = "329",

pages = "1204--1206",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - More on the Survival and Ventricular Enlargement Trial

AU - Ganley, C. J.

AU - Hung, H. M J

AU - Temple, R.

AU - Pfeffer, M. A.

AU - Moye, L. A.

AU - Rutherford, J.

AU - Braunwald, E.

PY - 1993/10/14

Y1 - 1993/10/14

N2 - To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves…

AB - To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves…

UR - http://www.scopus.com/inward/record.url?scp=0027363726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027363726&partnerID=8YFLogxK

U2 - 10.1056/NEJM199310143291616

DO - 10.1056/NEJM199310143291616

M3 - Letter

C2 - 8377799

AN - SCOPUS:0027363726

SN - 0028-4793

VL - 329

SP - 1204

EP - 1206

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

More on the Survival and Ventricular Enlargement Trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this